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Summary
 
We report here the identification of a new shared human melanoma antigen recognized by a
human leukocyte antigen (HLA)-A*68011–restricted cytotoxic T lymphocyte clone (CTL
128). The cDNA encoding this antigen is composed of a partially spliced form of the melano-
 
cyte differentiation antigen tyrosinase-related protein (
 
TRP
 
)-
 
2
 
, containing exons 1–4 with re-
tention of intron 2 and part of intron 4 (
 
TRP-2–INT2
 
). The sequence coding for the antigenic
 
epitope is located at the 5
 
9
 
 end of intron 2 and is available for translation in the same open
reading frame of the fully spliced 
 
TRP-2
 
 mRNA. This peptide is also recognized by CTL 128
when presented by the HLA-A*3301, a member of the HLA-A3–like supertype that includes
the HLA-A*68011. Quantitative reverse transcription PCR analysis carried out on total and/or
cytoplasmic mRNA demonstrated that, in contrast to the fully spliced 
 
TRP-2
 
 mRNA ex-
pressed in melanomas, normal skin melanocytes, and retina, the 
 
TRP-2–INT2
 
 mRNA could
be detected at significant levels in melanomas but not in normal cells of the melanocytic lin-
eage. Instead, in these normal samples, both the spliced and the unspliced transcript of 
 
gp100
 
were expressed at high levels. Absence of endogenous 
 
TRP-2–INT2
 
 expression in melanocytes
 
was also confirmed by lack of recognition of HLA-A*68011–transduced, TRP-2
 
1
 
 melanocyte
lines by CTL 128. These results indicate that a partially spliced form of a differentiation antigen
mRNA, present in the cytoplasmic compartment of neoplastic but not normal cells of the mel-
anocytic lineage, can be the source of a melanoma-restricted T cell epitope.
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S
 
everal studies have demonstrated the existence of an
MHC class I–restricted CTL response specifically di-
rected against human tumors (1). The role of such tumor-
specific effectors in mediating the regression of metastatic
melanomas has been suggested by the results of several clin-
ical trials of both adoptive immunotherapy (2, 3) and vacci-
nation (4–6). The determinants recognized by such CTLs
have been studied extensively on melanoma cells, and sev-
eral antigens have been characterized at the molecular level
(1). According to the pattern of gene expression in normal
and neoplastic cells, these antigens can be divided into
three classes which may have different clinical relevance.
The first class includes antigens that are shared between
melanomas and tumors of other histological type, but not
by normal tissues with the exception of testis and placenta
(1, 7, 8). However, these tissues, since they are negative for
expression of MHC class I molecules (9) needed for anti-
gen presentation, cannot be targeted by T cells. Clinical tri-
als based on the use of these antigens are in progress in pa-
tients affected by melanoma and other neoplastic diseases,
and no relevant side-effects have been detected in the
treated patients (1, 4).
The second class contains tissue-specific antigens ex-
pressed in normal and neoplastic cells of the melanocytic
lineage (1, 10–12). Recently, the treatment of HLA-A2
melanoma patients with a gp100 peptide, modified to in-
crease its binding to this HLA allele, in IFA plus IL-2, was
shown to be associated with a significant clinical response
rate (5). Even though no significant side-effects were ob-
served in that or other similar clinical studies, the develop-
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ment of cross-reacting responses against normal tissues (i.e.,
skin melanocytes and pigmented retinal cells) must be care-
fully considered when self-differentiation antigens are used
as vaccines (13).
The third class includes antigens expressed only by the
tumor cells from which they have been isolated (1), since
these antigenic epitopes are usually generated by a point
mutation occurring in otherwise ubiquitously expressed
proteins. The lack of natural tolerance against these anti-
gens may allow the induction of a strong immune response,
while avoiding the development of potential autoimmune
reactions. However, until a panel of widely shared muta-
tions has been discovered, the clinical application of such
antigens is limited to the treatment of those few patients
whose tumor carries the given mutation.
The existence of a fourth set of tumor antigens has been
recently suggested based on the pattern of reactivity of a
panel of CTL clones able to recognize the autologous and
HLA-matched allogeneic melanomas, but not melanocytes
or other targets of different histological origin (14). Here
we report the characterization of a melanoma antigen be-
longing to this group and found to be encoded by a re-
tained intron in a partially spliced transcript of the tyrosine-
related protein 2 (TRP-2)
 
1
 
 differentiation antigen.
The features of this new shared melanoma-specific anti-
gen may allow the development of safer and more effica-
cious immunotherapy trials.
 
Materials and Methods
 
Cell Lines.
 
The melanoma cell line Me18732 was established
from a metastatic lesion obtained from a surgical specimen of pa-
tient 18732, admitted for surgery to the Istituto Nazionale Tumori
(Milan, Italy). PBLs of this patient were typed serologically as HLA-
A2/28, -B44/51, -C2/5. The human metastatic (Me17697, Me-
2559/1, Me12657, Me17088/1, Me4023) and primary (Me20842)
melanoma cell lines, established in our laboratory, the carcinoma
lines CALU3, SKBR3, and SKOV3 (American Type Culture
Collection, Rockville, MD), and the WEHI-164.13 cells (15)
were cultured in 10% FCS/RPMI 1640. The melanoma lines
LB33, MZ2-MEL, and SK23-MEL, and the COS-7 cell line
were provided by Prof. T. Boon (Ludwig Institute for Cancer
Research, Brussels, Belgium) and maintained in 10% FCS/RPMI
1640 (melanomas) or 10% FCS/DMEM (COS-7). Normal hu-
man epidermal melanocyte lines (NHEM)-2489, -2311, and
-4528 (Clonetics, San Diego, CA), and DL-1 melanocytes, the gift
of Dr. M. De Luca (Istituto Dermopatico dell’Immacolata, Rome,
Italy), were kept in melanocyte growth medium (MGM-2;
Clonetics). The C1R-A*03301 transfectant, the homozygous
EBV-transformed lymphoblastoid cell line (LCL) SCHU (HLA-
A*0301, B*0702, C7), AMA-1 (HLA-A*6802, -B*5301, -C4),
and WT-100-bis (HLA-A11, B35, C4) were provided by Dr.
Soo Young Yang (Memorial Sloan-Kettering Cancer Center,
New York); the EBV-LCL JHAF (HLA-A*31011, -B51, -C8)
and LB (HLA-A*68011, -B*40011, -C2/3) were obtained from
 
American Type Culture Collection. EBV-LCL cells were main-
tained in 10% FCS/RPMI 1640. CTL 128 (CD3
 
1
 
, CD4
 
2
 
,
CD8
 
1
 
, TCR 
 
ab
 
1
 
) was derived and grown as described previ-
ously (14). Its lytic activity was tested in a standard chromium-
release assay (14) in the presence or absence of HLA-specific mAbs.
 
Subcloning of the HLA-A
 
*
 
68011 Allele.
 
cDNA obtained from
Me18732 total RNA was amplified by PCR using a primer pair
suitable for amplification and directional cloning of the HLA-A
full-length coding region (gift of Dr. Soo Young Yang). The
1.1-kb PCR product was subcloned into the eukaryotic expression
vector pcDNA3 (Invitrogen Corp., Abingdon, Oxon, UK). A
plasmid clone (pcDNA3/
 
A
 
*
 
6801
 
) encoding the HLA-A*68011
allele was identified by diagnostic restriction mapping and se-
quencing.
 
Construction and Screening of the cDNA Library.
 
Poly(A)
 
1
 
 RNA
was isolated from Me18732 cells using the FastTrack mRNA ex-
traction kit (Invitrogen Corp.). The library was constructed con-
verting 5 
 
m
 
g of poly(A)
 
1
 
 RNA to cDNA with the SuperScript
Choice System kit (GIBCO BRL, Gaithersburg, MD) using an
oligo-dT primer containing a NotI site at its 5
 
9
 
 end. cDNAs were
then ligated to BstXI adapters (Invitrogen Corp.) and digested
with NotI. After size fractionation, cDNAs were unidirectionally
cloned into the BstXI/NotI site of the mammalian expression
vector pcDNA3.1 (Invitrogen Corp.). Recombinant plasmids
were electroporated into DH5-
 
a
 
 
 
Escherichia coli
 
 and selected with
ampicillin (50 
 
m
 
g/ml). The library was divided into 1,300 pools
of 
 
z
 
100 cDNA clones. Each pool of bacteria was amplified to
saturation, and plasmid DNA was extracted and transfected (100
ng) together with pcDNA3/
 
A
 
*
 
6801
 
 (100 ng) into COS-7 cells
by the DEAE-dextran-chloroquine method (16). Using the same
technique, in other experiments COS-7 cells were cotransfected
with 100 ng of pcDNA3/
 
A
 
*
 
6801
 
 vector and 100 ng of expres-
sion vectors encoding one of the following melanoma antigens:
Melan-A/MART-1, tyrosinase, gp100, MAGE-1, -2, -3, -4, -12,
BAGE-1, -2, GAGE-1, -2, -3, -4, -5, -6 (provided by Dr. P. van
der Bruggen, Ludwig Institute for Cancer Research), TRP-1
(provided by Dr. R.S. Wang, National Cancer Institute, National
Institutes of Health, Bethesda, MD). Full-length 
 
TRP-2
 
 cDNA
was amplified by reverse transcription (RT)-PCR using specific
primers located in the 5
 
9
 
-untranslated region (UTR; PRIT-1b,
5
 
9
 
-GGAGAAAAGTACGACAG-3
 
9
 
) and at the end of exon 8
(TRP-2L, 5
 
9
 
-ACCCTAGGCTTCTTCTGTGTATCTCTT-3
 
9
 
),
cloned into pcDNA3, and sequenced to verify correspondence to
the published cDNA sequence (17). Transfected COS-7 cells or
stimulating cell lines were tested for their ability to induce TNF
release by CTL 128, as described previously (18).
 
DNA Sequencing.
 
Sequencing was performed with an auto-
mated DNA sequencer (ABI Prism 377; Perkin-Elmer Corp.,
Norwalk, CT) using the Dye Terminator Cycle Sequencing
Ready Reaction kit (Perkin-Elmer Corp.). The computer search
for the sequence homology was done with the program FASTA
EMBL-Heidelberg.
 
Production of Subfragments of cDNA 131.
 
Subfragments of cDNA
131 (5
 
9
 
-end 1500, 5
 
9
 
-end 800, 200, and 3
 
9
 
 end) were obtained by
digestion of the plasmid with HindIII and BstUI and cloned into
the pcDNAI plasmid (Invitrogen Corp.). From the 5
 
9
 
-end 1500,
the smaller fragments INT2-434, -166, and -107 were generated
by PCR amplification. The sense primer KS-INT2 (5
 
9
 
-GCC-
GCCATGTATTCTGTTAGAGATACA-3
 
9
 
) was used for am-
plification of all fragments. This primer generates an ATG start
codon (underlined), with the appropriate Kozak consensus se-
quence, in the same open reading frame (ORF) as 
 
TRP-2
 
. The
antisense primers used for amplification of the INT2-434, -166,
 
1
 
Abbreviations used in this paper:
 
 LCL, lymphoblastoid cell line; LNGFR,
low-affinity nerve growth factor receptor; nt, nucleotide(s); ORF, open
reading frame; RT, reverse transcription; TRP, tyrosinase-related pro-
tein; UTR, untranslated region. 
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and -107 fragments, respectively, were SP6 (5
 
9
 
-ATTTAGGT-
GACACTATAG-3
 
9
 
) located in the pcDNAI plasmid, INT2-as1
(5
 
9
 
-ATCCGCTCGAGCATGAAATTACTTCCC-3
 
9
 
), and INT2-
as2 (5
 
9
 
-ATCCGCTCGAGGATAATTCTACGAC-3
 
9
 
), located
in intron 2 of 
 
TRP-2
 
. The antisense primers INT2-as1 and -as2
contained an XhoI restriction site (underlined) for directional
cloning.
 
Retroviral HLA-A
 
*
 
68011 Gene Transfer into Melanocytes.
 
A ret-
roviral vector encoding the full-length 
 
HLA-A
 
*
 
68011
 
 cDNA,
under the control of the viral LTR, and the truncated form of the
human low-affinity nerve growth factor receptor (
 
D
 
LNGFR)
driven by the SV40 promoter was constructed as described previ-
ously (19). An amphotropic packaging cell line was established by
infection of the GP
 
1
 
env Am 12 line and immunoselection for
 
D
 
LNGFR expression by the use of magnetic beads (Dynabeads
M-450; Dynal A.S., Oslo, Norway) coated with the LNGFR-
specific mAb 20.4 (American Type Culture Collection). Trans-
duction of melanocytes and SK23-MEL was performed by culti-
vation with retrovirus-containing supernatant in the presence of
polybrene (0.8 mg/ml). Three rounds of infection of at least 4 h
were performed.
 
Separation of Nuclear and Cytoplasmic RNA.
 
Cells (2–3 
 
3 
 
10
 
6
 
)
were harvested, washed with PBS, and then carefully resuspended
in 400 
 
m
 
l of buffer A (10 mM Hepes, pH 8.0, 10 mM KCl, 0.1
mM EDTA, 0.1 mM EGTA, 1 mM dithiothreitol). After 10 min
of incubation on ice, cytoplasmic membranes were disrupted by
the addition of 20 
 
m
 
l NP-40 (10%), and the suspension was vig-
orously vortexed for 10 s and then centrifuged for 30 s at 15,000
rev/min. The supernatant containing the cytoplasmic RNA was
transferred to a new tube. The pellet containing the intact nuclei
was washed with buffer A to eliminate residual cytoplasmic
RNA. Cytoplasmic and nuclear RNAs were purified from the
cell fractions using the RNeasy mini kit (QIAGEN Inc., Chats-
worth, CA). The absence of contaminating nuclear material (i.e.,
DNA and nuclear mRNA) in the cytoplasmic compartment was
checked with specific primers flanking at least one intron of
 
MAGE-3
 
 (20) or complementary to intron–exon junctions flank-
ing exon 8 of 
 
p53
 
 (21).
 
Expression of TRP-2 and Its Partially Spliced Form TRP-2–INT2.
 
cDNA corresponding to 150 ng of total RNA from melanoma
lines and fresh samples (tumors, skin, and retina) was amplified
by PCR in 25 
 
m
 
l of water containing 200 
 
m
 
M of each dNTP,
0.6 
 
m
 
M of each primer, 1
 
3
 
 PCR buffer, 1 U of Taq-Gold (all
reagents from Perkin-Elmer Corp.). 
 
TRP-2
 
 cDNA was amplified
using the sense primer PR3 located in exon 2 (5
 
9
 
-TTC-
GGCAGAACATCCATTCC-3
 
9
 
) and the TRP-2L antisense
primer, originating an amplicon of 1186 bp. 
 
TRP-2–INT2
 
 was
amplified using the sense primer PRIT-1b and the antisense
primer INT2-1260 (5
 
9
 
-ACCTCACCAACTCACATCTT-3
 
9
 
),
located in the 5
 
9
 
-UTR and in intron 2, respectively, and giving
an amplification product of 977 bp. PCR amplification was per-
formed for 30 cycles: 1 min at 94
 
8
 
C, 1 min at 55
 
8
 
C (58
 
8
 
C for
 
TRP-2
 
), and 1 min at 72
 
8
 
C. Primer positions were chosen in or-
der to avoid contamination from genomic DNA. 
 
Glyceraldehyde-
3-phosphate-dehydrogenase
 
 (
 
GAPDH
 
) cDNA was amplified with
specific primers (22).
 
Evaluation of Primer Pair Sensitivity.
 
Plasmids containing 
 
TRP-
2–INT2
 
, 
 
TRP-2
 
, and 
 
gp100 cDNAs were suspended to 10 pg/ml,
a concentration equivalent to 1,026,119, 1,193,338, and 1,251,907
molecules/ml, respectively, serially twofold diluted, and amplified
by PCR under the conditions described above. To mimic the
target complexity of “true” cDNA sample, cDNA corresponding
to 50 ng of total RNA from the carcinoma line SKBR3, negative
for expression of TRP-2, TRP-2–INT2, and gp100, was added.
TRP-2 was amplified with primers PR3 and TRP-2L. For TRP-
2–INT2, in addition to PRIT-1b and INT2-1260, we also tested
the sense primer PR15 (59-AATTGGCAGTTCCAGTGTCC-
39), located in intron 2, and the antisense primer PR16 (59-AT-
TGCAGGTACAGGAGCCAT-39), located in intron 4, giving
an amplicon of 906 bp. To amplify gp100, a previously described
primer pair giving an amplicon of 361 bp was used (23). After an
initial incubation at 948C for 10 min and a final incubation at
728C for 7 min, temperature cycling was conducted, with minor
modifications, according to the original stepdown PCR parame-
ters (24). Cycling was repeated 37 times, divided into 6 groups,
with a denaturation of 20 s at 948C and an elongation of 1 min 15 s
at 728C. The six groups consisted of three, six, six, six, nine, and
seven cycles. Annealing temperatures lasted 40 s and decreased by
38C from one group of cycles to the next, starting at 648C in the
first three cycles, 618C in the following six, etc., and ending with
508C in the last seven cycles. For gp100, extension time at 728C
lasted for 1 min in all cycles. Amplification products were size
fractionated on agarose gels in the presence of ethidium bromide,
digitally acquired under UV transillumination (Eagle Eye II, Still
Video System; Stratagene Inc., La Jolla, CA), and analyzed densi-
tometrically (ImageQuant version 3.3 software; Molecular Dy-
namics, Sunnyvale, CA). For each primer pair, the OD of gel
bands (expressed in arbitrary units on a linear scale) was plotted
against the initial concentration (expressed in picograms per mi-
croliter on a logarithmic scale) of target plasmid present in the
sample. The minimum concentration of target plasmid detectable
by each primer pair was indicated by the lowest point in the lin-
ear amplification range of the curve. The mean of this value,
evaluated in three experiments and expressed as number of mole-
cules, was considered as the sensitivity of each primer pair.
Quantitative RT-PCR Analysis. cDNA samples prepared from
total or cytoplasmic RNA of Me18732 were used as a reference,
i.e., a sample whose level of expression of a given transcript is ar-
bitrarily defined as 100%. GAPDH expression was used to nor-
malize experimental results. The linear amplification range of
GAPDH, TRP-2, gp100, TRP-2–INT2, and gp100-in4 was de-
termined experimentally for the reference Me18732 cDNAs,
starting from 2 ml cDNA, a volume corresponding to 100 ng total
RNA. For each primer pair, the appropriate number of cycles to
attain exponential amplification was found for a certain range of
dilutions, varying the number of the final cycles of the stepdown
PCR, performed as described above. The total number of cycles
for GAPDH was 22 (groups of 3, 6, 6, and 7 cycles), and for
gp100, TRP-2–INT2, TRP-2, and gp100-in4 was 30, 33, 35, and
40, respectively, according to groups of 3, 6, 6, 6, 9 plus n cycles.
TRP-2 was amplified by primer pair PR3 plus TRP-2L; TRP-
2–INT2 by PR15 plus PR16; and gp100, gp100-in4, and
GAPDH by a pair of published primers (10, 22, 23). Linear re-
gression analysis of experimental OD values allowed construction
of standard curves for Me18732. Serial dilutions of cDNAs from
all samples to be quantified were analyzed in these cycling condi-
tions. Their OD values were compared with the appropriate stan-
dard curve always included in each PCR run, and normalized to
the expression level of the GAPDH gene.
The lowest point in the linear amplification range of the cali-
bration curve of a given primer pair, corresponding to a dilution
expressed as a percentage of the first dilution of Me18732 cDNA,
arbitrarily taken as 100%, was considered the minimum sensitivity
threshold for that primer pair. The absence of a detectable ampli-
fication product, or OD values falling below this threshold, were
reported as less than this threshold value. For primer pair PR31008 A New CTL-defined Melanoma Antigen
plus TRP-2L (TRP-2) the threshold was 0.01%, and for PR15
plus PR16 (TRP-2–INT2) 0.1%. To quantify the level of TRP-
2–INT2 expression in fresh specimens (skin and retina samples) in
which the proportion of melanocytic cells is unknown and vari-
able, the method described was modified as follows. The same
cDNA dilutions from Me18732 total RNA were amplified using
31 (for TRP-2) and 33 (for TRP-2–INT2) cycles of stepdown
PCR; after densitometric analysis, the OD results were expressed
in arbitrary units. cDNA dilutions of skin and retina samples were
amplified with TRP-2 primers for n number of cycles (ranging
from 40 to 45) in order to obtain, after amplification, an OD of
the gel band within the range covered by the Me18732 cDNA.
For TRP-2–INT2, the same quantities of starting material were
amplified for n plus at least 2 cycles to reflect the difference in the
number of cycles (31–33) needed to detect TRP-2 and TRP-
2–INT2, respectively, in the reference melanoma.
Peptides and CTL Assays. The  TRP-2–INT2 sequence was
analyzed at a Web site of the National Institutes of Health (http:
//bimas.dcrt.nih.gov:80/molbio/hla_bind/) for the presence of
potential HLA-A*68011–binding peptides. Lyophilized pep-
tides, 90% pure as indicated by analytical HPLC, were purchased
from Primm Srl (Milan, Italy), dissolved at 10 mM concentration
in DMSO, and stored at 2808C. Various concentrations of the
peptides were added to 51Cr-labeled target cells. After 1 h of in-
cubation at room temperature, CTL 128 was added at an E/T ra-
tio of 20:1. Lysis was measured 4 h later. Alternatively, stimulator
cells were incubated for 1 h at room temperature with a fixed
concentration of peptides; after extensive washing, CTL 128 was
added, and the TNF release was evaluated 18–20 h later on
WEHI-164.13 cells.
Results
Identification of HLA-A*68011 as Restriction Element for
CTL 128. Melanoma cell line Me18732 was established
from a metastatic lesion of patient 18732. Lymphocytes of
the patient were typed as HLA-A2 and HLA-A28 by sero-
logical methods and then as HLA-A*0201 and HLA-
A*68011 (hereafter referred to as HLA-A*6801) by se-
quence-specific oligonucleotide probe (SSOP) subtyping
(25). HLA-restricted antitumor CTL clones were obtained
from mixed lymphocyte tumor culture, as described (14).
In particular, CTL clone 128 recognized the autologous
tumor, and its lytic activity was inhibited by an mAb rec-
ognizing HLA-A2 and -A28, but not by an anti–HLA-A2
and -A69 mAb, indicating that HLA-A28 (A*6801) was
the restricting molecule for CTL 128 (data not shown).
Antigen Specificity of CTL 128. To evaluate the frequency
of expression of the antigen recognized by CTL 128, a
panel of HLA-A*6801 tumor lines was tested in a CTL
stimulation assay. Five out of eight melanoma cell lines in-
duced TNF release by CTL 128 (Fig. 1). However, no re-
activity was observed with three HLA-A*6801 carcinoma
lines of different histological origin (Fig. 1). The pattern of
reactivity displayed by CTL 128 towards the melanoma
lines tested did not correlate with expression of previously
described melanoma antigens in these cell lines, as assessed
by RT-PCR (data not shown). This was confirmed by the
lack of TNF release by CTL 128 in the presence of COS-7
cells cotransfected with plasmid pcDNA3/A*6801, to-
gether with most of the cDNAs known to encode shared
melanoma antigens (see Materials and Methods; data not
shown). These results suggested that CTL 128 recognized a
new antigen shared by a number of melanomas.
Cloning of a cDNA Encoding the Melanoma Antigen Recog-
nized by CTL 128. A cDNA library was constructed in
expression vector pcDNA3.1 with poly(A)1 RNA ex-
tracted from Me18732 cells. Plasmid DNA from pools of
100 recombinant clones was cotransfected into COS-7 cells
together with plasmid pcDNA3/A*6801. The DNA of
one pool induced the production of a high level of TNF by
CTL 128 (data not shown). By subcloning the bacteria of
this pool, we obtained several clones that were able to
transfer expression of the antigen. The results obtained
with one of these clones, cDNA 131, are shown in Fig. 2.
Recognition of the antigen was independent of the high,
artificial expression level achieved in COS-7 cells. Indeed,
an HLA-A*68011 melanoma cell line that was not recog-
Figure 1. Recognition by CTL 128 of HLA-A*68011 melanoma and
carcinoma cell lines. 1.5 3 103 CTLs were added to 2.5 3 104 stimulator
cells, and the TNF content of the supernatant was tested 20 h later on
WEHI-164.13 cells.
Figure 2. Stimulation of CTL 128 by COS-7 cells transfected with
cDNA 131 and HLA-A*6801 cDNA. COS-7 cells were transfected with
HLA-A*6801 and with cDNA 131. The production of TNF by CTL
128 was measured after 24 h of coculture with the transfected cells, using
the TNF-sensitive cell line WEHI-164.13. As control, COS-7 cells were
transfected with cDNA 131 or HLA-A*6801 alone.1009 Lupetti et al.
nized by CTL 128 acquired, when transfected with cDNA
131, the ability to induce TNF release, and became sensi-
tive to lysis by CTL 128 (data not shown). The sequence of
the cDNA 131 proved to be 3535 bp long (Fig. 3), with
nucleotides (nt) 1–994 and 3081–3347 identical to two
noncontiguous regions of TRP-2 cDNA (17), which has
been recently identified as a melanoma antigen of the mela-
nocyte lineage (12). The first region contained exon 1,
whose 59-UTR lacked the first 15 bases, and exon 2, whereas
the second region encompassed exons 3 and 4, of the
TRP-2 gene, respectively. The sequences between nt 995
and 3080 and that downstream of nt 3347 showed no sig-
nificant homology with any sequence recorded in the data-
banks, and were likely to be retained intron sequences. In-
deed, a stretch of 10 amino acids flanking the exonic
portions matched the described sequences at exon–intron
junctions of the TRP-2 gene (26). The length of sequence
995–3080 (2086 nt) was comparable with intron 2 of TRP-2,
as deduced from the published genomic map, and the se-
quence downstream of nt 3347 of cDNA 131 presented a
59 donor splice site sequence identical to that of intron 4 of
TRP-2 (26). Since it lacks the 39 acceptor splice site se-
quence and its length is considerably shorter than that esti-
mated from the published genomic map, we concluded
that this was the sequence of intron 4 of TRP-2, truncated
at nt 176. Sequencing of intron 4, amplified by PCR from
genomic DNA of Me18732, revealed the presence of a
polyadenine stretch of 10 nt, starting from nt 177 (data not
shown). This finding supports the hypothesis of a fortuitous
priming of this sequence by the oligo-dT used for con-
struction of the cDNA library. Thus, cDNA 131 appeared
to be composed of a partially spliced form of the melanocyte
differentiation antigen TRP-2, containing exons 1–4 with
retention of intron 2 and the initial portion of intron 4.
Identification of the Sequence Encoding the Peptide Recognized
by CTL 128. Three subfragments of z1.5, 0.2, and 2 kb,
respectively (59-end 1500, 200, and 39 end; Fig. 4), were ob-
tained by digesting cDNA 131 with HindIII, then cloned
into pcDNAI vector and transfected into COS-7 cells along
with pcDNA3/A*6801. At this step, the presence in the
200 and 39-end fragments of start codons regulating their
translation was not investigated. The level of TNF released
by CTL 128 in the presence of COS-7 cells transfected
with the 59-end 1500 fragment was comparable to that
stimulated by cDNA 131 (Fig. 4), indicating that the anti-
genic peptide was encoded within this region. Since CTL
128 was not stimulated by COS-7 cells cotransfected with
both the fully spliced TRP-2 cDNA and HLA-A*6801
(Fig. 4), we hypothesized that the sequence coding for the
antigen recognized by CTL 128 could be entirely or par-
tially located in the intronic portion of the TRP-2 gene
present in cDNA 131. This notion received support by the
lack of recognition of COS-7 cells transfected with the 59-
end 800 cDNA fragment (Fig. 4), derived by truncation of
the 59-end 1500 fragment at a BstUI site and comprising
exon 1 and half of exon 2. The intronic localization of the
sequence encoding the antigenic peptide was confirmed by
the ability of a PCR-amplified fragment encompassing the
first 434 bp of intron 2 (INT2-434; see Materials and
Methods) to convey expression of the antigen (Fig. 4). A
sequence that coded for a decapeptide (EVISCKLIKR; Fig.
3) that possessed anchor residues (positions 2, 9, and 10)
corresponding to the HLA-A*6801 peptide-binding motif
(27) was present in the same ORF of the previous exons.
The sense primer KS-INT2 (which generates an ATG
start site with the appropriate Kozak consensus sequence)
and the reverse primer INT2-as1 or INT2-as2 (Fig. 3)
were used to generate fragments including (INT2-166) or
not (INT2-107) the entire putative peptide-encoding se-
quence. Only fragment INT2-166 was able to stimulate
TNF release by CTL 128 (Fig. 4). Both 10- and 9-mer
peptides, EVISCKLIKR and EVISCKLIK, were then syn-
thesized and incubated with the HLA-A*6801 homozy-
gous LCL line LB. The decapeptide was able to sensitize
LB cells to lysis by CTL 128, with half-maximum lysis ob-
Figure 3. Sequence of cDNA 131. The ATG start codon of the TRP-2
cDNA, and the first stop codon (TAG) in the same ORF, are doubly un-
derlined. Exonic and intronic sequences are uppercase and lowercase, re-
spectively. Positions of the primers used in the study for amplification of
TRP-2–INT2 are indicated by horizontal arrows. The nucleotide se-
quence coding for the antigenic peptide (bold) recognized by CTL 128 is
translated in the corresponding amino acid sequence using the single letter
amino acid code. The nucleotide sequence is available under GenBank
accession no. AJ000503.1010 A New CTL-defined Melanoma Antigen
tained at a concentration of z100 pM, whereas the nona-
peptide had a very low efficiency (Fig. 5). A control pep-
tide, WTGPNCERKK, derived from exon 2 of the fully
spliced TRP-2 gene (17) able to bind to HLA-A*6801, was
not recognized (data not shown). Given the localization
of the antigenic epitope within intron 2 of TRP-2, the
antigen was named TRP-2–INT2 and the epitope TRP-
2–INT2222-231.
To exclude the possibility that TRP-2–INT2222-231 may
have been generated by a mutation that occurred in the tu-
mor, a 2152-bp fragment spanning the entire intron 2 (nt
995–3080 in cDNA 131) was amplified by PCR from ge-
nomic DNA of CTL 128 and from a different melanoma,
MZ2-MEL. The PCR products were cloned, sequenced,
and transfected together with pcDNA3/A*6801 into COS-7
cells. All clones had the expected sequences and were able
to transfer expression of the antigen (data not shown).
Presentation of the Antigenic Peptide by Alleles of the HLA-
A3–like Supertype. HLA-A*6801, along with A3, A11, A31,
and A*3301, belongs to an A3-like supertype of HLA-A
alleles with similar peptide-binding characteristics (28). To
investigate whether the TRP-2–INT2222-231 peptide can be
presented to CTL 128 by HLA alleles of the A3-like super-
type, EBV LCL cells expressing such alleles were used as
targets for CTL 128 after pulsing with the peptide. Among
the A3-like supertype alleles, only A*3301 was able to
present TRP-2–INT2222-231 peptide with the same effi-
ciency as A*6801 (Fig. 6).
Expression of the Sequence Encoding TRP-2–INT2 in Tu-
mors and Normal Tissues. Expression of transcripts retain-
ing intron 2 was analyzed by RT-PCR with the PRIT-1b
plus INT2-1260 primer pair. The completely spliced
TRP-2 messenger was detected with the PR3 plus TRP-2L
primer pair. Among the tumors tested, only melanomas
proved positive for TRP-2 and TRP-2–INT2 expression
(Table 1), whereas 17 carcinomas (4 ovary, 4 breast, 4 lung,
2 pancreas, and 3 bladder) were negative (data not shown).
84% (16 out of 19) and 68% (13 out of 19) of melanoma
cell lines analyzed expressed TRP-2 and TRP-2–INT2, re-
spectively. In fresh melanoma samples, the normal form of
TRP-2 was expressed in 69% (9 out of 13) of the analyzed
samples and TRP-2–INT2 in 54% (7 out of 13; Table 1).
Expression of TRP-2–INT2 in the absence of TRP-2 was
never observed. This result is in agreement with the notion
that TRP-2 is a melanocytic differentiation antigen (12)
and that the same promoter drives the synthesis of a com-
mon messenger from which both antigens arise. Normal
tissues in which TRP-2 is known to be present were ana-
lyzed for TRP-2–INT2 expression. 4 melanocyte cell lines,
13 skin samples, and 1 retina tested were all negative in the
RT-PCR assay (Table 1).
Quantitative RT-PCR Analysis for TRP-2–INT2 Expres-
sion. To quantitate levels of expression of TRP-2 and
TRP-2–INT2 in both neoplastic and normal cells, primer
pair sensitivity (i.e., the minimum number of target mole-
cules detectable) as well as amplification efficiency had to
be comparable. As detailed in Materials and Methods, seri-
Figure 4. Identification of the
sequence coding for the anti-
genic peptide recognized by
CTL 128. Top left, Exon–intron
organization of cDNA 131. Ex-
ons (black boxes) and introns
(white boxes) are indicated; the
horizontal line at the extremities
represents pcDNA3.1 vector; the
numbering of the sequence is
relative to the 59 end of cDNA
131. Subfragments derived from
cDNA 131 and PCR products,
shown below cDNA 131, were
cloned into expression vectors
and transfected into COS-7 cells
with the HLA-A*6801 cDNA,
and those recognized by CTL
128 (striped boxes) are indicated.
The peptide-encoding sequences
present in the PCR fragments
INT2-166 and INT2-107 are
shown (bottom left). The spliced
full-length form of TRP-2 cDNA was obtained by PCR as described (see Materials and Methods). TNF release by CTL 128 was evaluated on WEHI-
164.13 cells (right). Striped bars, Recognition of cDNA 131 and its subfragments.
Figure 5. Lysis by CTL 128 of
HLA-A*6801 cells pulsed with
the synthetic peptide EVISCK-
LIKR (TRP-2–INT2222-231).
51Cr-labeled HLA-A*6801 LCL
line LB was pulsed for 2 h at
room temperature with the syn-
thetic peptides EVISCKLIKR
(filled circles) and EVISCKLIK
(open circles) and incubated with
CTL 128 at an E/T ratio of 20:1,
at the concentration indicated.
51Cr release was measured after
4 h of coincubation.1011 Lupetti et al.
ally diluted plasmids containing TRP-2, TRP-2–INT2, and
gp100 cDNA were amplified for 37 cycles with specific
primers. After densitometric analysis, the sensitivity of the
PR3 plus TRP-2L primer pair was determined in the order
of 34 molecules for TRP-2, whereas 19 was the lowest
number of molecules of gp100 detectable with the previ-
ously described primers (23). For TRP-2–INT2, the primer
pair PR15 plus PR16, which displays an even higher sensi-
tivity (four molecules), was chosen for this analysis. All
primer pairs showed a nearly identical amplification effi-
ciency, as indicated by parallelism of regression lines in the
linear amplification range of the curves (data not shown).
Therefore, levels of expression of TRP-2 and TRP-
2–INT2 in nine melanoma cell lines were determined by
quantitative RT-PCR on cDNA derived from total RNA.
Me18732 was arbitrarily considered to have 100% expres-
sion of these genes and was used as the reference standard
(Table 2). All measurements were normalized on GAPDH
expression to take into account differences in template in-
tegrity. Expression of TRP-2–INT2 in the absence of
TRP-2 was never observed. The six tumor lines that stimu-
lated TNF release by CTL 128 expressed both TRP-2 and
TRP-2–INT2. The level of expression of TRP-2–INT2
mRNA ranged from 6 to 187% of that present in
Me18732, and that of TRP-2 from 5 to 35%. Among the
three melanoma lines not recognized by CTL 128, LB33
was below the threshold of sensitivity of the primer pair
used for expression of both transcripts, whereas Me17088/1
expressed low levels (0.1%) of TRP-2 mRNA only; MZ2-
MEL*6801, a melanoma cell line stably transfected with
HLA-A*6801, expressed low levels of both TRP-2 (0.5%)
and TRP-2–INT2 (0.4%). Since RT-PCR analysis per-
formed on total RNA does not distinguish the cytoplasmic,
partially spliced TRP-2–INT2, from which the antigenic
peptide is generated, from pre–TRP-2 mRNA of nuclear
origin, RNA was extracted from both the nucleus and the
cytosol of MZ2–MEL-A*6801. A strong PCR signal was
obtained from nuclear RNA, whereas the TRP-2–INT2
message in the cytoplasm accounted for 0.2% of that
present in the same compartment of Me18732. The ab-
sence of TNF release by CTL 128 in the presence of
MZ2–MEL-A*6801 demonstrates that cytoplasmic TRP-
Figure 6. Recognition by CTL
128 of the TRP-2–INT2221-231
peptide when presented by HLA
alleles of the A3-like supertype.
51Cr-labeled LCL cells were incu-
bated with CTL 128 at an E/T
ratio of 20:1, in the presence of
peptide TRP-2–INT2222-231 at
different concentrations. 51Cr
release was measured after 4 h of
coincubation.
Table 1. Expression of TRP-2–INT2 and TRP-2 mRNA in 
Tumors and Normal Tissues
No. of samples with antigen 
expression/no. samples tested*
TRP-2–INT2 TRP-2
Melanoma cell lines 13/19 (68%)‡ 16/19 (84%)
Melanocyte cell lines 0/4 4/4
Fresh melanoma samples 7/13 (54%)‡ 9/13 (69%)
Skin 0/13 13/13
Retina 0/1 1/1
Carcinomas 0/17 ND
*cDNA synthesis and PCR were performed as described in Materials
and Methods.
‡TRP-2–INT2 expression was detected only in samples positive for
TRP-2.
Table 2. Quantitative RT-PCR of TRP-2 and TRP-2–INT2 
mRNA Expression and Recognition by CTL Clone 128
Melanoma cell lines
Recognition
by CTL 128 TRP-2–INT2* TRP-2*
Me18732 1 100 100
Me12657 1 187 34
Me20842 1 28 17
Me2559/1 1 65
Me4023 1 55 22
SK23–MEL-A*6801‡ 1 15 35
MZ2–MEL-A*6801‡ 2 0.4 0.5
Me17088/1 2, 0.1 0.1
LB33 2, 0.1 ,0.01
*Expression of TRP-2–INT2 and TRP-2 mRNA in the different mel-
anoma samples was assessed by quantitative RT-PCR. Me18732 was
arbitrarily considered to have 100% expression of these genes, and the
limit of detection for TRP-2–INT2 and TRP-2 was 0.1 and 0.01%, re-
spectively.
‡Cell line obtained by calcium-phosphate transfection of pcDNA3/
A*6801 and selection in G418. Expression of the transfected HLA-
A*6801 allele was verified by flow cytometry with specific mAbs (data
not shown).1012 A New CTL-defined Melanoma Antigen
2–INT2 transcript levels of at least .0.2% of that found in
Me18732 are needed for functional recognition of target
cells.
To exclude the possibility of even low contamination of
pre–TRP-2 nuclear message, quantitative analysis of TRP-2
and TRP-2–INT2 expression in four melanocyte cell lines
at their first in vitro passages was performed with cDNA
derived from cytoplasmic RNA. Expression levels of gp100
and its partially spliced form gp100-in4 mRNAs, contain-
ing sequences coding for CTL-defined antigens expressed
by melanomas and melanocytes (1, 10), were also included
in the analysis. As reported in Table 3, TRP-2–INT2
mRNA of the cultured skin melanocytes was either unde-
tectable (3/4) or at the lower limit of detection (1/4),
whereas TRP-2 mRNA ranged from 15 to 614% of that
expressed by Me18732. However, all melanocyte lines ex-
pressed  gp100 and particularly gp100-in4 at high levels,
from 79 to 1,613% and from 776 to 5,000%, respectively,
of that found in Me18732. Fig. 7 shows the gel bands used
for densitometric analysis.
We then examined samples of three TRP-21 normal
skin tissue and one retina. Since in fresh specimens the pro-
portion of melanocytic cells is variable and generally very
low, we used a slightly modified protocol, detailed in Ma-
terials and Methods. Total RNA was analyzed, since at-
tempts to separate nuclei from cytoplasmic compartments
were unsuccessful, as demonstrated by a consistent level of
nuclear contamination in cytoplasm (data not shown), due
to the high level of cellular damage and/or deaths resulting
from the enzymatic treatment used to prepare single cell
suspensions. Results are reported in the original OD values
and are shown in Fig. 8. An amplification product for
TRP-2  was obtained in each of the four samples (three skin
tissue and one retina) analyzed, whereas TRP-2–INT2 was
undetectable. In this case too, both gp100 and gp100-in4
were expressed at high levels (data not shown).
The absence of expression of endogenous TRP-2–INT2
in normal melanocytic cells was also confirmed by the lack
of recognition by CTL 128 of melanocyte lines transduced
with HLA-A*6801 (data for the DL-1 line are shown in
Fig. 9). The transduced HLA-A*6801 molecule was able to
present the endogenous TRP-2–INT2 product as shown by
recognition of the HLA-A*6801–transduced SK23-MEL.
Moreover, expression of HLA-A*6801 by the transduced
melanocytes was confirmed by their ability to functionally
present the exogenously provided TRP-2–INT2222-231 pep-
tide to CTL 128.
Taken together, these results indicate that the presence
of a transcript corresponding to the unspliced TRP-2 gene
accompanies TRP-2 mRNA expression in the cytoplasmic
compartment of the majority of melanoma cells. This phe-
nomenon does not occur in normal cells, despite the pres-
ence of comparable or even higher levels of TRP-2, allow-
ing a partially spliced form of a differentiation antigen
encoding mRNA to become the source of a melanoma-
restricted T cell epitope.
Discussion
This study reports the molecular identification of an an-
tigen (TRP-2–INT2) belonging to a new class of shared
melanoma antigens absent from melanocytes. The epitope
recognized by HLA-A*6801–restricted CTL 128 is en-
coded within intron 2 of a partially spliced mRNA of the
TRP-2 gene. In its completely spliced form, TRP-2 is a
member of the tyrosinase-related gene family encoding an
enzyme acting in the melanogenic pathway and containing
an epitope recognized in an HLA-restricted fashion by T
cells on melanomas and melanocytes (12). The sequence
coding for the peptide recognized by CTL 128 is located at
Table 3. Quantitative RT-PCR of TRP-2–INT2, 
TRP-2, gp100, and gp100-in4 mRNAs in the Cytoplasm of 
Human Melanocytes
Cytoplasmic mRNA TRP-2–INT2 TRP-2 gp100-in4 gp100
%
Me18732 100 100 100 100
NHEM-2489 ,0.1 21 776 79
NHEM-2311 ,0.1 133 1039 360
NHEM-4528 0.1 614 2363 155
DL-1 ,0.1 15 5000 1613
Expression of the different transcripts was measured by quantitative
RT-PCR. Me18732 was arbitrarily considered to have 100% expres-
sion of these genes. The limit of detection for TRP-2–INT2 was 0.1%.
Figure 7. Quantitative RT-PCR analy-
sis. Serial twofold dilutions of cDNA de-
rived from cytoplasmic RNA of DL-1 and
NHEM-4528 melanocytes were amplified
and simultaneously compared with the ref-
erence Me18732, as described in Materials
and Methods. Depending on the sample and
on the gene tested, starting dilutions ranged
from 0 to 211 (i.e., 20 5 undiluted, 2211 5
1/2,048). Results obtained after densito-
metric scanning of the amplified products
are shown in Table 3.1013 Lupetti et al.
the 59 end of intron 2, which is available for translation be-
cause of a failure in the splicing pathway. An increasing
body of evidence suggests the immunological significance
of unconventionally produced epitopes. Indeed, epitopes
encoded in alternative ORFs (29), within introns (10, 16),
under the putative control of a cryptic promoter (30), or
governed by a variant of conventional translation mecha-
nisms (31) have been described. It has also been proposed
that the increased expression in splice variants of pigment
genes that occurs in melanoma compared with normal
melanocytes may contribute to the pool of melanoma-spe-
cific antigenic peptides (32).
TRP-2–INT2 expression was not observed in melano-
mas lacking TRP-2. Moreover, no TRP-2–INT2 was
found when TRP-2 expression was 0.1% of that found in
Me18732. Such a low level of TRP-2 transcription, de-
tected by the very sensitive quantitative RT-PCR, could
not be evidenced in Northern blots (data not shown) and
probably accounts for the percentage of TRP-21 fresh mel-
anomas that fail to express TRP-2–INT2. In all normal tis-
sues containing TRP-21 cells of melanocytic origin (i.e.,
skin and retina) and in three out of four melanocyte sam-
ples that had levels of TRP-2 ranging from 21 to 133% of
that expressed by Me18732, TRP-2–INT2 was undetect-
able (Table 3, and Figs. 7 and 8). Furthermore, TRP-2–INT2
was still at the lower threshold of detectability (i.e., 0.1%)
in a melanocyte line that displayed more than a sixfold
increase (614%) of TRP-2 compared with Me18732 (Table
3, and Fig. 7). Transduction of melanocyte lines with the
HLA-A*6801 allele confirmed the absence of endogenous
TRP-2–INT2222-231 expression at levels allowing CTL 128
recognition (Fig. 9).
Northern blot analysis has indicated that TRP-2 and, in
general, pigment gene expression are low in human mela-
noma compared with the average expression in melano-
cytes (33). This finding was confirmed by our quantitative
PCR analysis in which two out of four melanocyte lines
had increased levels of TRP-2 over that of Me18732, one
of the tumors that displayed the highest level of expression
for this gene (Tables 2 and 3). We had similar findings with
gp100,  whose levels of expression in three out of four
melanocyte lines were 1.3–16 times higher than those of
Me18732. Given the lower expression of TRP-2 in trans-
formed compared with normal cells, these results rule out
the possibility that the presence of the unspliced form of
the TRP-2 gene in melanoma is simply related to high lev-
els of gene transcription. Rather, our findings suggest that
the splicing pathway that involves this gene is operating in
normal melanocytes but is altered in melanoma cells, al-
lowing the transport of certain intron-containing transcripts
into the cytoplasm. As also observed for gp100-in4 by Rob-
bins et al., the intron-encoded epitope is expressed after
transfection into COS-7 cells (10). Lack of adjacent regula-
tory sequences might be responsible for the splicing failure
in COS-7 cells (34), since our cDNA clone is probably
Figure 8. Expression of TRP-2–INT2 and
TRP-2 on normal tissues. Expression was
tested by quantitative RT-PCR on cDNA
derived from total RNA. Results are ex-
pressed in arbitrary OD units (a.u.) after
densitometric analysis of the amplified prod-
ucts, as described in Materials and Methods.
For Me18732, the plotted OD points for
TRP-2 and TRP-2–INT2 correspond to four
identical and consecutive serial dilutions,
chosen in order to obtain, with the lowest
one, a still detectable amplification signal for
TRP-2–INT2. Amplification of TRP-2
from normal samples was performed in con-
ditions (i.e., cDNA amount and cycle num-
ber) allowing the attainment of an OD value
included in the range covered by Me18732.
TRP-2–INT2 was consequently amplified
using comparable parameters (see Materials
and Methods). (Insets) OD arbitrary units
(a.u.) are reported for normal samples.
Figure 9. Lack of recognition by CTL 128 of HLA-A*68011–trans-
duced melanocytes. DL-1 melanocytes and the SK23-MEL lines were
transduced by a retroviral vector encoding HLA-A*6801. 1.5 3 103
CTLs were added to 104 transduced and untransduced stimulator cells,
and the TNF content of the supernatant was tested 20 h later on WEHI-
164.13 cells. Efficiency of transduction was evaluated by the ability of the
transduced cells to present the TRP-2–INT2222-231 peptide.1014 A New CTL-defined Melanoma Antigen
truncated at its 39 end by a fortuitous priming of a polyade-
nine stretch in intron 4. However, the presence of un-
spliced mRNAs in the cytoplasm cannot be considered a
distinguishing feature of transformed cells, but appears to
be gene specific. Indeed, weak consensus sequences at in-
tron–exon boundaries may determine a very low splicing
efficiency and ubiquitous retention of intervening se-
quences in mRNA even in normal cells (35). Moreover,
although the mechanism has not been investigated, expres-
sion of the unspliced form of the differentiation antigen
gp100  (gp100-in4) has been found in normal melanocytes at
levels comparable to or even higher than that found in
melanomas (10), a finding confirmed by our quantitative
PCR analysis (Table 3).
TRP-2–INT2 codes for a putative protein of 237 amino
acids that runs, using the same ORF of TRP-2, from the
start codon in position 400 to the terminator site (nt 1111)
located in intron 2, just 18 nt downstream of the peptide-
coding region. Wild-type TRP-2 protein (519 amino ac-
ids) was identified as the DOPAchrome tautomerase in-
volved in melanin biosynthesis (17, 36). The TRP-2–INT2
translation product, devoid of the transmembrane domain,
is expected to have a different localization from TRP-2,
which exists as a melanosome membrane-bound form.
Therefore, the functional role, if any, of TRP-2–INT2 in
the tumor cells needs to be addressed.
Although the minimum level of TRP-2–INT2 mRNA
expression allowing CTL-mediated recognition has not
been established, an HLA-A*6801 melanoma line express-
ing in its cytoplasmic compartment 0.2% of the level found
in Me18732 failed to induce TNF production by CTL 128.
However, a melanoma line (Me 2559/1) expressing TRP-
2–INT2 at levels equal to 6% of that found in Me18732
(Fig. 1, and Table 2) was recognized. On the basis of the
frequency of hybridizing cDNA colonies, Me18732 ap-
pears to express z20 TRP-2–INT2 mRNA molecules per
cell (data not shown). Accordingly, 6% expression corre-
sponds to one molecule per cell and could be considered
the minimum level of TRP-2–INT2 that allows CTL 128–
mediated recognition. This level of expression is lower
than that required for CTL recognition of most of the
other melanoma antigens (37, 38), suggesting that CTL
128 is a high-affinity effector. The HLA-binding affinity of
the TRP-2–INT2222-231 peptide is unknown, but the very
low concentration (100 pM) required to sensitize cells to
lysis (see Fig. 5) supports this hypothesis. Detection of
high-affinity effectors specific for epitopes encoded by intron
2 suggests that this sequence may be a source of “non-self”
antigenic epitopes. Indeed, CTLs recognizing autoantigens
have been shown to escape intrathymic clonal deletion only
when expressing low-affinity receptors, while high-affinity
CTLs against autoantigens are deleted (39). Furthermore,
in peptide sensitization assays, many differentiation anti-
gen–derived peptides are active only at concentrations
higher than those of the tumor-specific peptides (40).
Taken together, these observations strongly indicate that
TRP-2–INT2 codes for a new type of tumor antigen
shared among melanomas, but absent in normal tissues.
Analysis of the structural similarities in the antigen-bind-
ing groove of HLA molecules and the identification of
cross-reactive peptides have allowed grouping of HLA al-
leles into supertypes (41). Based on its peptide-binding
characteristics, HLA-A*6801 belongs to the HLA-A3–like
supertype that also comprises A3, A11, A31, and A*3301
(28). Among the alleles of the A3-like supertype, recogni-
tion of TRP-2–INT2222-231 peptide was also observed
when it was presented by A*3301, which, along with
A*6801, is expressed by 13% of the world’s population
(28). It has been previously reported that identical peptides
derived from viral proteins (HBcAg from hepatitis B) or
from tumor antigens (TRP-2) can be recognized in the
context of different HLA alleles, HLA-A31 and A68 or
HLA-A31 and A33, respectively, by specific and differentially
HLA-restricted CTL clones (42, 43). Moreover, in agree-
ment with our findings, single T cells have been shown to
recognize a TRP-2 melanoma–associated peptide when
presented by both HLA-A31 and A*3301 (43).
Apart from the TRP-2–INT2222-231 peptide, screening
introns and intron–exon junctions of TRP-2–INT2 for the
presence of known motifs revealed peptide sequences that
are predicted to bind with high efficiency several HLA-A
and -B alleles, including HLA-A2, frequently present in all
major ethnic groups. This suggests that other tumor anti-
gens with the same degree of lineage and tumor specificity
may be expressed by melanoma cells in the context of more
frequent HLA-A and -B alleles. Furthermore, it is possible
that other specific antigens can be generated in melanoma
and other tumors by mechanism(s) of altered splicing of
lineage-related genes.
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